推薦產品
品質等級
化驗
≥95% (HPLC)
形狀
powder
顏色
white to beige
溶解度
DMSO: 2 mg/mL, clear
儲存溫度
-10 to -25°C
InChI
1S/C23H20N6O/c24-19-5-1-2-6-21(19)28-22(30)17-9-7-16(8-10-17)14-27-23-26-13-11-20(29-23)18-4-3-12-25-15-18/h1-13,15H,14,24H2,(H,28,30)(H,26,27,29)
InChI 密鑰
HRNLUBSXIHFDHP-UHFFFAOYSA-N
生化/生理作用
MGCD0103 (Mocetinostat) is an orally active, potent and subtype-selective histone deacetylase (HDAC) inhibitor (IC50: class I HDAC1/2/3 = 0.15/0.29/1.66 μM, class IV HDAC11 = 0.59 μM, HDAC4/5/7/8 >10 μM) that effectively inhibits cellular HDAC activity (IC50 = 450 nM; Du145, HCT15, HCT116), resulting in an upregulated acetylation of histone H3 and H4, but not that of tubulin. MGCD0103 daily orally administration (60-120 mg/kg) is efficacious against A549 & H1437 tumor growth in mice in vivo.
儲存類別代碼
11 - Combustible Solids
水污染物質分類(WGK)
WGK 3
閃點(°F)
Not applicable
閃點(°C)
Not applicable
BioMed research international, 2020, 4705615-4705615 (2020-08-11)
The use of histone deacetylase (HDAC) inhibitor is a novel therapeutic strategy for cardiovascular disease. Studies have shown that many HDAC inhibitors have the ability to reduce the aortic remodeling in various animal models. We hypothesized that the HDAC inhibitor
我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務